Dr Reddy's Lpb launches generic version of Imitrex(R) Tablets

Hyderabad, Nov 24 (UNI) Dr Reddy's Laboratories (NYSE:RDY) today announced that it has launched the authorised generic version of GlaxoSmithKline's Imitrex(R) (sumatriptan succinate) tablets in 25mg, 50mg, and 100mg strengths in the United States.

Dr Reddy's is the first company to do so, a Company release said.

In October 2006, the company announced that it had settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline Imitrex(R) tablets. The specific financial terms and conditions of the settlement have not been disclosed.

GlaxoSmithKline Imitrex(R) tablets, which are indicated for the treatment of migraine attacks in adults, had US. sales of 1.29 billion dollars for the 12-month period ending December 2007 according to IMS.

UNI SM VV RSA RN2144